Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis.

Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. BMC Neurol (2009) 1.17

C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J Neurol (2009) 1.05

C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. Inflammation (2012) 0.94

Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med (2009) 0.92

TTC7B emerges as a novel risk factor for ischemic stroke through the convergence of several genome-wide approaches. J Cereb Blood Flow Metab (2012) 0.91

Osteopontin predicts long-term functional outcome among ischemic stroke patients. J Neurol (2010) 0.88

C-reactive protein and long-term ischemic stroke prognosis. J Clin Neurosci (2013) 0.87

Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis. J Neurol (2008) 0.85

Plasma C-Reactive Protein and Clinical Outcomes after Acute Ischemic Stroke: A Prospective Observational Study. PLoS One (2016) 0.82

Creatine kinase MM TaqI and methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms influence exercise-induced C-reactive protein levels. Eur J Appl Physiol (2011) 0.81

Follow-up C-reactive protein level is more strongly associated with outcome in stroke patients than admission levels. Neurol Sci (2015) 0.78

Creatine kinase MM TaqI and methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms influence exercise-induced C-reactive protein levels. Eur J Appl Physiol (2011) 0.76

Are C-reactive protein levels before thrombolysis of prognostic value? Nat Clin Pract Neurol (2006) 0.75

Admission C-reactive protein as a predictor for stroke outcome among candidates for thrombolysis: decision adjourned. Stroke (2006) 0.75

The Relationship between C-Reactive Protein Level and Discharge Outcome in Patients with Acute Ischemic Stroke. Int J Environ Res Public Health (2016) 0.75

Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns. Neurotherapeutics (2016) 0.75

Predictive role of high sensitive C-reactive protein in early onset mortality after ischemic stroke. Iran J Neurol (2012) 0.75

[Baseline predictors of outcome in stroke patients treated with intravenous thrombolysis--the Austrian stroke unit registry]. Wien Med Wochenschr (2008) 0.75

Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78

Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med (2015) 6.96

Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med (2004) 5.32

Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93

Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol (2009) 3.36

Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol (2012) 2.94

Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke (2007) 2.93

Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet (2012) 2.69

Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol (2010) 2.31

Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation (2003) 2.30

Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke (2006) 2.27

Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke (2005) 2.24

Tandem internal carotid artery/middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis. Stroke (2006) 2.20

Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients. Stroke (2003) 2.20

Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest (2003) 2.20

Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke (2008) 2.10

Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke (2007) 2.03

Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke (2004) 1.91

Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation. Circ Res (2003) 1.89

Diffusion-weighted MR imaging in the acute phase of transient ischemic attacks. AJNR Am J Neuroradiol (2002) 1.83

Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke (2002) 1.83

Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke (2004) 1.81

Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke. Stroke (2002) 1.80

C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke (2003) 1.78

Trevo System: single-center experience with a novel mechanical thrombectomy device. J Neuroimaging (2011) 1.73

Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. Stroke (2004) 1.70

Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke (2003) 1.67

MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke (2007) 1.66

Bridging intravenous-intra-arterial rescue strategy increases recanalization and the likelihood of a good outcome in nonresponder intravenous tissue plasminogen activator-treated patients: a case-control study. Stroke (2011) 1.64

Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke (2003) 1.61

Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab (2006) 1.56

Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke (2008) 1.54

Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage. Stroke (2008) 1.52

Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke (2009) 1.52

Is it time to reassess the SITS-MOST criteria for thrombolysis?: A comparison of patients with and without SITS-MOST exclusion criteria. Stroke (2009) 1.51

[Factors influencing CRP levels in the diabetic population]. Med Clin (Barc) (2005) 1.47

IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke (2012) 1.45

Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab (2009) 1.43

Impact of onset-to-reperfusion time on stroke mortality: a collaborative pooled analysis. Circulation (2013) 1.41

[Intravenous tissue-type plasminogen activator for the treatment of acute cerebral ischemia]. Med Clin (Barc) (2003) 1.41

[Clinical benefit following the implementation of a specialized urgent stroke care system]. Med Clin (Barc) (2004) 1.40

Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol (2008) 1.37

A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A (2005) 1.34

Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke (2012) 1.33

Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg (2003) 1.27

Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke (2009) 1.26

Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke (2002) 1.24

Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial. Stroke (2011) 1.22

Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? Ann N Y Acad Sci (2010) 1.18

Futile recanalization in mechanical embolectomy trials: a call to improve selection of patients for revascularization. Stroke (2010) 1.17

Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques. Stroke (2006) 1.17

The association of the 4q25 susceptibility variant for atrial fibrillation with stroke is limited to stroke of cardioembolic etiology. Stroke (2010) 1.17

Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke (2005) 1.16

Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res (2007) 1.16

Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem (2009) 1.15

Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke (2005) 1.12

Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma (2009) 1.12

Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J Proteome Res (2009) 1.11

Extending the time window for endovascular procedures according to collateral pial circulation. Stroke (2011) 1.11

Association of a genetic variant in the ALOX5AP with higher risk of ischemic stroke: a case-control, meta-analysis and functional study. Cerebrovasc Dis (2010) 1.10

Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke (2004) 1.09

A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis (2011) 1.09

A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke (2005) 1.08

Plasma S100B level after acute spontaneous intracerebral hemorrhage. Stroke (2006) 1.08